CREDX

𝐏𝐢𝐭'𝐬 "𝐀𝐈 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐞𝐚𝐦 𝐚𝐬 𝐚 𝐬𝐞𝐫𝐯𝐢𝐜𝐞" 𝐥𝐞𝐚𝐫𝐧𝐬 𝐡𝐨𝐰 𝐚𝐧 𝐞𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐞𝐬 𝐚𝐧𝐝 𝐛𝐮𝐢𝐥𝐝𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧-𝐠𝐫𝐚𝐝𝐞 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐭𝐨 𝐫𝐮𝐧 𝐢𝐭. 𝐀𝟏𝟔𝐳'𝐬 𝐑𝐚𝐦𝐩𝐞𝐥𝐥 𝐬𝐚𝐢𝐝: "𝐅𝐨𝐫 𝟐𝟎 𝐲𝐞𝐚𝐫𝐬, 𝐞𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐡𝐚𝐯𝐞 𝐫𝐞𝐧𝐭𝐞𝐝 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐭𝐡𝐚𝐭 𝐟𝐨𝐫𝐜𝐞𝐬 𝐭𝐡𝐞𝐦 𝐭𝐨 𝐨𝐩𝐞𝐫𝐚𝐭𝐞 𝐚𝐫𝐨𝐮𝐧𝐝 𝐢𝐭. 𝐖𝐢𝐭𝐡 𝐀𝐈, 𝐭𝐡𝐚𝐭 𝐞𝐧𝐝𝐬." 𝐈𝐬 𝐏𝐢𝐭'𝐬 𝐦𝐨𝐝𝐞𝐥 𝐠𝐞𝐧𝐮𝐢𝐧𝐞𝐥𝐲 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐟𝐫𝐨𝐦 𝐛𝐞𝐬𝐩𝐨𝐤𝐞 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 — 𝐨𝐫 𝐢𝐬 𝐭𝐡𝐢𝐬 𝐧𝐚𝐫𝐫𝐚𝐭𝐢𝐯𝐞 𝐩𝐚𝐜𝐤𝐚𝐠𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐦𝐨𝐫𝐞 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐦𝐨𝐝𝐞𝐥 ?



The genuine difference is the continuous learning and autonomous update capability — and it is worth scrutinising rather than accepting at face value. Traditional bespoke software development: a consulting team interviews stakeholders, builds a specification, codes the software, hands it off to the client's IT team to maintain. When business processes change, the client initiates a change request, pays for development time, and waits. Pit's described model: the AI platform observes how operations actually work (not how they are described in a specification), builds software to match, and continues to update as operations evolve. The autonomous update capability — if genuine and reliable at production scale — is the category distinction.



The honest uncertainty: "autonomously updating production software as operations evolve" is an extremely high bar for AI reliability. A software update that misinterprets an operational change could cause cascading failures in systems that clients depend on. The deployments in logistics and telecom that Pit has announced will either validate or disprove this claim at production scale over the next 12-18 months. Rampell's framing ("holds up for years") is the commitment — watching whether the deployments confirm it is the appropriate journalistic and investor follow-up.



#Funding #CredX #Startup #AI

2 hours ago | [YT] | 0

CREDX

𝐏𝐢𝐭'𝐬 "𝐀𝐈 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐞𝐚𝐦 𝐚𝐬 𝐚 𝐬𝐞𝐫𝐯𝐢𝐜𝐞" 𝐥𝐞𝐚𝐫𝐧𝐬 𝐡𝐨𝐰 𝐚𝐧 𝐞𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐞𝐬 𝐚𝐧𝐝 𝐛𝐮𝐢𝐥𝐝𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧-𝐠𝐫𝐚𝐝𝐞 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐭𝐨 𝐫𝐮𝐧 𝐢𝐭. 𝐀𝟏𝟔𝐳'𝐬 𝐑𝐚𝐦𝐩𝐞𝐥𝐥 𝐬𝐚𝐢𝐝: "𝐅𝐨𝐫 𝟐𝟎 𝐲𝐞𝐚𝐫𝐬, 𝐞𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐡𝐚𝐯𝐞 𝐫𝐞𝐧𝐭𝐞𝐝 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐭𝐡𝐚𝐭 𝐟𝐨𝐫𝐜𝐞𝐬 𝐭𝐡𝐞𝐦 𝐭𝐨 𝐨𝐩𝐞𝐫𝐚𝐭𝐞 𝐚𝐫𝐨𝐮𝐧𝐝 𝐢𝐭. 𝐖𝐢𝐭𝐡 𝐀𝐈, 𝐭𝐡𝐚𝐭 𝐞𝐧𝐝𝐬." 𝐈𝐬 𝐏𝐢𝐭'𝐬 𝐦𝐨𝐝𝐞𝐥 𝐠𝐞𝐧𝐮𝐢𝐧𝐞𝐥𝐲 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐟𝐫𝐨𝐦 𝐛𝐞𝐬𝐩𝐨𝐤𝐞 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 — 𝐨𝐫 𝐢𝐬 𝐭𝐡𝐢𝐬 𝐧𝐚𝐫𝐫𝐚𝐭𝐢𝐯𝐞 𝐩𝐚𝐜𝐤𝐚𝐠𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐦𝐨𝐫𝐞 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐦𝐨𝐝𝐞𝐥 ?



The genuine difference is the continuous learning and autonomous update capability — and it is worth scrutinising rather than accepting at face value. Traditional bespoke software development: a consulting team interviews stakeholders, builds a specification, codes the software, hands it off to the client's IT team to maintain. When business processes change, the client initiates a change request, pays for development time, and waits. Pit's described model: the AI platform observes how operations actually work (not how they are described in a specification), builds software to match, and continues to update as operations evolve. The autonomous update capability — if genuine and reliable at production scale — is the category distinction.



The honest uncertainty: "autonomously updating production software as operations evolve" is an extremely high bar for AI reliability. A software update that misinterprets an operational change could cause cascading failures in systems that clients depend on. The deployments in logistics and telecom that Pit has announced will either validate or disprove this claim at production scale over the next 12-18 months. Rampell's framing ("holds up for years") is the commitment — watching whether the deployments confirm it is the appropriate journalistic and investor follow-up.



#Funding #CredX #Startup #AI

2 hours ago | [YT] | 0

CREDX

The Gates Foundation invested in Kanvas Biosciences's Series A — a US clinical-stage oncology company. The Gates Foundation does not invest for financial return. They invest where they have evaluated global health impact potential.



Their participation in Kanvas signals: microbiome-based checkpoint inhibitor synergy therapy has potential for deployment in low- and middle-income country oncology settings where second-line options are limited. That global access framing changes Kanvas's incentive structure permanently — there is now a global health stakeholder on the cap table alongside the financial investors.



#Startup #Business #India

3 hours ago | [YT] | 0

CREDX

CellCentric — $220M Series D. Lead: Venrock Healthcare Capital Partners. Participating: Sofinnova Partners, RA Capital Management, HBM Healthcare Investments AG, Pfizer. Total: $400M+. Headquarters: Cambridge (UK) and Boston. Lead drug: inobrodib — first-in-class p300/CBP inhibitor for multiple myeloma, a type of blood cancer.



Use of proceeds: Phase 2/3 clinical trials and manufacturing scale-up. Pfizer participating as a strategic investor signals both the clinical credibility of inobrodib's mechanism and Pfizer's interest in blood cancer pipeline assets at a time when its oncology portfolio is under pressure from biosimilar competition.



#Funding #CredX #Update #CellCentric

23 hours ago | [YT] | 0

CREDX

Prior Labs — $1.16B strategic investment from SAP. Prior Labs is a European sovereign AI company building enterprise AI infrastructure. SAP's $1.16 billion investment is the largest single corporate AI infrastructure investment in European history by a software major.



Prior Labs now has strong corporate backing and will expand its engineering team and labs. The SAP investment makes Prior Labs one of Europe's most heavily capitalised AI labs — by a significant margin — and signals SAP's strategic determination to control its own AI infrastructure layer rather than depending on US or Chinese AI providers.



#Funding #CredX #Startup #Prior

1 day ago | [YT] | 1

CREDX

India macro: Freshworks Freshworks reported 16% revenue growth in Q1 2026 and simultaneously cut 11% of its global workforce — around 500 employees. Both attributed to AI. This is the first major public company to disclose that AI-driven productivity gains are large enough to reduce headcount while revenue grows. The combination — more revenue, fewer employees — is what AI productivity looks like in public company financial statements. Every enterprise SaaS company now has a public benchmark to be measured against. Full CREDX May 6 at credx.club

1 day ago | [YT] | 0

CREDX

QuantWare + Corgi double QuantWare raised $178M — the largest quantum processor private round ever. Intel Capital co-led. The CIA's In-Q-Tel also invested. The company calls itself the TSMC of quantum computing: neutral open-architecture manufacturer for the entire quantum ecosystem. VIO-40K architecture for 10,000 qubits — 100x the current state of the art.



Oversubscribed. Meanwhile, Corgi Insurance raised $160M at $1.3B from TCV — four months after its Series A. Emily Yuan and Nico Laqua built the first AI-native licensed insurance carrier from YC Summer 2024. Full carrier license in 12 months. Instant quotes, same-day binding. YC's fastest 2026 unicorn.



#Funding #CredX #Startup

1 day ago | [YT] | 0

CREDX

Blitzy raised $200M. They built a platform that reverse-engineers an entire enterprise codebase, builds a dynamic knowledge graph of how everything connects, and then coordinates thousands of AI agents in parallel for weeks to build entire software projects autonomously. SWE-Bench Pro score of 66.5% — the highest ever recorded.



5x engineering velocity. Dozens of Global 2000 customers. The founders: an Army Ranger and an Nvidia Master Inventor who met at Harvard. I keep thinking about the architectural insight: a single AI model can't hold 100 million lines of code in its context window. But a knowledge graph can. That's the technical distinction that makes this work at enterprise scale. Full



#Funding #CredX #Startup

1 day ago | [YT] | 0

CREDX

Vobiz AI— $1M seed. Lead: Piper Serica VC Fund. Founders: Suman Gandham and Vikash Srivastava — former Finin and Plivo executives. AI-first telephony infrastructure for Voice AI products.



Offers instant DID provisioning, SIP trunking, real-time call streaming, noise cancellation, and telecom compliance tools. India's enterprise voice AI infrastructure layer — the plumbing that makes AI voice agents work at scale without latency or regulatory issues.



#Funding #CredX #AI #India

1 day ago | [YT] | 0

CREDX

MedVital — ₹18Cr (~$2.2M) growth round. Lead: Alkemi Growth Capital. Participating: Sanjay Arora, Shubhan Ventures, existing investors.



Founded 2024. Wound care and regenerative aesthetics medtech — develops medical technologies across advanced wound care, regenerative aesthetics, and chronic skin conditions.



#Funding #CredX #Startup

1 day ago | [YT] | 0